S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|BioCryst Pharmaceuticals Announces the Appointment of Lynne Powell as Chief Commercial Officer (2015/1/5)|
|BioCryst shares rally on positive opinion from Europe for angioedema drug (2015/1/14)|
|BioCryst Reports Fourth Quarter & Full Year 2014 Financial Results (2015/2/18)|
|BioCryst Initiates OPuS-2: A Clinical Trial of BCX4161 in Patients With Hereditary Angioedema (2014/12/18)|
|BioCryst Receives Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema (2014/12/23)|
|BioCryst's RAPIVAB(TM) (peramivir injection) Receives FDA Approval for the Treatment of Acute Uncomplicated Influenza (2014/12/22)|
|BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection (2014/12/23)|
|BioCryst Receives Positive Opinion on European Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema (2015/1/14)|
|FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary Angioedema (2015/1/26)|
|BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4430 for the Treatment of Hemorrhagic Fever Viruses (2014/12/15)|
Click above to view more mutual fund data and stats for bcrx - Biocryst Pharmaceuticals Inc.